Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens

• Published in: Cancer chemotherapy and pharmacology Vol. 46; no. 2; pp. 119 - 127
• Main Authors: HUITEMA, A. D. R, KERBUSCH, T, TIBBEN, M. M, RODENHUIS, S, BEIJNEN, J. H
• Format: Journal Article
• Language: English
• Published: Berlin Springer 2000
• Subjects: Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Biological and medical sciences; Biotransformation; Chemotherapy; Cyclophosphamide - administration & dosage; Cyclophosphamide - analogs & derivatives; Cyclophosphamide - blood; Cyclophosphamide - pharmacokinetics; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Medical sciences; Microsomes - metabolism; Neoplasms - blood; Neoplasms - drug therapy; Pharmacology. Drug treatments; Thiotepa - administration & dosage; Thiotepa - pharmacokinetics; Time Factors; Antineoplastic agent; Human; Drug combination; Digestive system; Liver; Aziridine derivatives; Malignant tumor; Metabolism; In vitro; In vivo; Alkylating agent; Chemotherapy; Cyclophosphamide; Oxazaphosphinane derivatives; Treatment; Nitrogen mustard; Thiotepa; Drug interaction; Pharmacokinetics; High dose; Organic thioamidophosphate

Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens. During a pharmacokinetic study of 31 courses in 20 patients of cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide given in the combination cyclophosphamide thioTEPA carboplatin,...